PMID- 7537575
OWN - NLM
STAT- MEDLINE
DCOM- 19950607
LR  - 20190719
IS  - 0918-6158 (Print)
IS  - 0918-6158 (Linking)
VI  - 18
IP  - 1
DP  - 1995 Jan
TI  - Analysis of antitumor properties of effector cells stimulated with a cell wall 
      preparation (WPG) of Bifidobacterium infantis.
PG  - 148-53
AB  - Intestinal Bifidobacterium species are thought to be beneficial in animal and 
      human intestines. We studied the mechanisms of Bifidobacteria in antitumor 
      activity using a cell wall preparation (WPG) of B. infantis (Cancer Res., 45, 
      1300, (1985)). WPG enhanced the in vitro antitumor activities of mouse peritoneal 
      exudate cells elicited with proteose-peptone (P-PEC) and thioglycollate broth 
      (TG-PEC), determined by cytostatic ([3H]thymidine uptake inhibition) and 
      cytolytic ([3H]uridine release) assays. Tumor necrosis factor-alpha (TNF-alpha) 
      and reactive nitrogen intermediates (RNI) play a role in such augmented 
      cytotoxicity, because anti-TNF-alpha antibody almost completely blocked the 
      increased cytolytic activity of P-PEC in the presence of WPG. Moreover, WPG 
      induced RNI in the supernatant of TG-PEC in a dose-dependent manner. The mRNA 
      expression of several cytokines (IL-1 beta, IL-6, IL-10, IFN-alpha and TNF-alpha) 
      was induced in BALB/c mouse peritoneal cells 3 h after an intraperitoneal 
      injection of WPG (3 h WPG-PEC). However, this expression disappeared from 24 h 
      WPG-PEC, except for that of IFN-alpha. IFN-gamma was not induced. Kinetic studies 
      of the tumor neutralizing activities of the WPG-PECs by means of the in vivo Winn 
      assay revealed that the activity emerged at 1.5 h, became maximal at 3 h and 
      disappeared at 24h. These results indicated that Bifidobacterial WPG is a 
      Biological Response Modifier (BRM) with characteristics similar to those of other 
      bacterial BRMs.
FAU - Sekine, K
AU  - Sekine K
AD  - Bio-Chemical Research Laboratory, Morinaga Milk Industry Co., Ltd., Kanagawa.
FAU - Ohta, J
AU  - Ohta J
FAU - Onishi, M
AU  - Onishi M
FAU - Tatsuki, T
AU  - Tatsuki T
FAU - Shimokawa, Y
AU  - Shimokawa Y
FAU - Toida, T
AU  - Toida T
FAU - Kawashima, T
AU  - Kawashima T
FAU - Hashimoto, Y
AU  - Hashimoto Y
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - 0 (Culture Media)
RN  - 0 (Cytokines)
RN  - 0 (Nitrites)
RN  - 0 (Peptidoglycan)
RN  - 0 (Peptones)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - EC 2.7.7.49 (RNA-Directed DNA Polymerase)
SB  - IM
MH  - Animals
MH  - Base Sequence
MH  - Bifidobacterium/*chemistry/ultrastructure
MH  - Cell Survival/drug effects
MH  - Cell Wall/*chemistry
MH  - Culture Media
MH  - Cytokines/biosynthesis
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C3H
MH  - Molecular Sequence Data
MH  - Nitrites/metabolism
MH  - Peptidoglycan/chemistry/isolation & purification/*pharmacology
MH  - Peptones/pharmacology
MH  - Peritoneal Cavity/cytology
MH  - Polymerase Chain Reaction
MH  - RNA-Directed DNA Polymerase
MH  - Sarcoma, Experimental/*drug therapy
MH  - Stimulation, Chemical
MH  - T-Lymphocytes, Regulatory/*drug effects/ultrastructure
MH  - Tumor Necrosis Factor-alpha/pharmacology
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
AID - 10.1248/bpb.18.148 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 1995 Jan;18(1):148-53. doi: 10.1248/bpb.18.148.